BackTable Urology
Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay
Dr. Rana McKay
I think in the metastatic setting, I think in general continuous, but, you know, there are caveats to that. And I think a lot of the caveats stem from what PSMA PET imaging has done in the field, what Saber has done in the field with regards to localized treatment for metastatic disease, particularly in individuals with oligometastatic disease.
0
💬
0
Comments
Log in to comment.
There are no comments yet.